Barring a complete disaster, I think we can relax and assume safety is going to be cleared fine now.
Which means safety is pretty much already priced into the current market cap. Maybe a little bump when they release some PK results?
Although I wonder how they are validating BBB penetration in this P1. They are only evaluating bloods. How come no CSF?
I expect that the next rerate will not happen until speculation right before P2 results. A CR or two before then will keep the brakes on unfortunately.
We might also get a little bump if patents are granted. It's a bit worrying not having IP protection...
NYR Price at posting:
10.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)